NOTICE OF THE ANNUAL GENERAL MEETING IN NEXAM CHEMICAL HOLDING AB (PUBL)

Nexam Chemical has convened its Annual General Meeting for 3:00 p.m. on Tuesday, May 12, 2026 at Elite Hotel Ideon in Lund. Record date is Monday, May 4, 2026 (shareholders must be listed in the Euroclear Sweden AB register) and shareholders must notify the company in writing of attendance and number of assistants by Wednesday, May 6, 2026.

Analysis

The narrow record-date / notification mechanics and Swedish Euroclear custody plumbing create a short, high-leverage window for governance-minded investors. Institutional and international holders who are not properly staged in local custody often have materially lower turnout, so a concentrated domestic buyer or an activist can convert modest capital (low-single-digit percent stakes) into outsized voting influence over the AGM agenda. Expect borrow demand and special-costs in the securities-lending market to spike in the days leading into the record window, which magnifies short squeezes for any defensive short positions.

The most likely second-order moves from management around AGMs in this segment are requests for pre-authorized share issuances, incentive-plan approvals, or board refresh mandates — all of which can be executed quickly after shareholder sign-off and have asymmetric effects on minority holders. Authorization to issue shares is a binary accelerator for potential dilutive financing or strategic M&A, and its mere proposal often compresses free-float and raises implied cost-of-capital ahead of execution. Conversely, a failed authorization can trigger management credibility questions and create a re-rating opportunity if activists push for alternative value-realization (sale, carve-out, higher R&D discipline).

Timing matters: the actionable window to accumulate voting power is measured in trading days around the record-date; the realization of any governance-driven value is typically a 3–12 month path, not instantaneous. Tail risks include emergency capital raises or insider-friendly recapitalizations that can wipe out equity holders; the immediate reversal trigger would be a sudden high-turnout block of long-only international holders (or a proxy-advisor negative opinion) mobilizing to defeat management proposals. Monitor securities-lending rates, custody confirmations with Euroclear, and any sudden insider buys/sells as proximate signals that the AGM outcome has tilted one way or the other.

Key Decisions for Investors

• Build a small activist-sized long position in Nexam Chemical (physical shares) prior to the record window — target 3–8% economic exposure, horizon 6–12 months. Risk/reward: aim for +30–70% upside if you secure a board seat or force a change of capital-allocation policy; downside is concentrated-illiquidity risk and potential dilution — size position to permit a 25% stop-loss.
• Hedge dilution risk using derivatives or swaps: enter short-equivalent exposure via an equity swap or borrow-and-short representing 30–50% of your long position for the record-to-AGM period. Timeframe: immediate (days–weeks). Reward: protects against a negative vote (share issuance approval); risk: borrow costs can spike and squeezes are possible, so cap carry to expected financing savings.
• Event-arbitrage play: accumulate a long position pre-record date and set up a contingent liquidity plan to monetize within 1–3 months post-AGM if management wins broad authorizations. Execute limit sell orders to capture a 20–40% re-rating and revisit if a sale process is launched. Risk: if authorization is used for hostile dilution, cut exposure quickly.
• If lacking desire to hold physical stock, pursue economic exposure via CFDs or total-return swaps that exclude voting rights to avoid being on the registrar — useful for trading directional governance speculation with lower operational overhead. Keep tenor <12 months and size to portfolio risk budget; downside is counterparty and funding risk.